2020 Annual Shareholder Meeting - provectusbio.com

2020 Annual Shareholder Meeting

Wednesday, June 24th

10025 Investment Drive, Suite 250, Knoxville, Tennessee, USA 37932 ?

Forward-Looking Statements

This presentation may contain forward-looking statements as defined under U.S. federal securities laws. These statements reflect Company management's current knowledge, assumptions, beliefs, estimates, and expectations, and express Provectus management's current views of future performance, results, and trends. These forward-looking statements may also be identified by their use of terms, such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, goal, strategy, target, will, and other similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the Company's actual results to materially differ from those described during this presentation. Readers of this presentation should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and Provectus undertakes no obligation to update such statements after this date. Risks and uncertainties that could cause the Company's actual results to materially differ from those described in these forward-looking statements include those discussed in Provectus' filings with the U.S. Securities and Exchange Commission (SEC) and those described in Item 1A of the Company's Annual Report on Form 10K for the year ended December 31, 2019, and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. Provectus Biopharmaceuticals, Inc. (Provectus or the Company) assumes no obligation to update any forward-looking statements or information that speaks as to their respective dates. No claims of safety or efficacy are intended with respect to Provectus' existing investigational drugs (PV-10? for oncology or PH-10? for dermatology) or potential future drug candidates (based on new modes of delivery of the Company's lead, proprietary, active pharmaceutical ingredient rose bengal [RB]) in the context of any forward-looking statements made in this presentation.

? 2020, Provectus Biopharmaceuticals, Inc.

2

Today's Agenda

o Shareholder Meeting Activities

o Company Update

- Welcome/Introduction

- Opening Remarks

- Preliminary Matters - Order of Business/Other Business - Inspector of the Election Report - Conclusion

- Developing a New Generation of Immunotherapy Medicines

-Q&A - Closing Remarks

? 2020, Provectus Biopharmaceuticals, Inc.

3

Part 1: Shareholder Meeting Activities

? 2020, Provectus Biopharmaceuticals, Inc.

4

Activities

o Welcome o Introductions o Preliminary Matters

- Inspector of the Election - Record Date - Shares Entitled to Notice and Vote - Quorum - Reading of the Notice of the

Meeting, Affidavit of Mailing, and Minutes - Stockholders' Proxies - Stockholders' Ballots

o Order of Business - Proposal #1: To elect 5 directors to serve on our Board of Directors for a 1-year term - Proposal #2: To conduct an advisory vote to approve the compensation of our named executive officers - Proposal #3: To ratify the selection of Marcum LLP as our independent registered public accounting firm

o Other Business

o Report of the Inspector of the Election

o Conclusion of the Meeting

? 2020, Provectus Biopharmaceuticals, Inc.

5

Part 2: Company Update

? 2020, Provectus Biopharmaceuticals, Inc.

6

Opening Remarks

Ed Pershing, CPA, Chair, Board of Directors

? 2020, Provectus Biopharmaceuticals, Inc.

7

Developing a New Generation of Immunotherapy Medicines

Dominic Rodrigues, Vice Chair, Board of Directors

? 2020, Provectus Biopharmaceuticals, Inc.

8

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download